Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVA-LTE long-term safety extension of mavacamten in hypertrophic cardiomyopathy
NL-OMON54979Phase 3Active, not recruiting
- Sponsor
- MyoKardia
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of mavacamten in hypertrophic cardiomyopathy (HCM) (3 arms), sponsored by MyoKardia. Started Jan 2020; status: active, not recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON54979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54979.